Free Trial
NASDAQ:INVO

INVO Bioscience (INVO) Stock Price, News & Analysis

INVO Bioscience logo
$1.68 -0.10 (-5.62%)
As of 05/23/2025

About INVO Bioscience Stock (NASDAQ:INVO)

Key Stats

Today's Range
$1.66
$1.80
50-Day Range
$1.61
$2.74
52-Week Range
$0.63
$3.50
Volume
167,461 shs
Average Volume
1.59 million shs
Market Capitalization
$6.40 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

INVO Bioscience, Inc., together with its subsidiary, a healthcare services fertility company, provides assisted reproductive technology solutions worldwide. It offers INVOcell, a medical device that allows fertilization and early embryo development to take place in vivo within the woman's body. The company was founded in 2007 and is based in Sarasota, Florida.

Receive INVO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for INVO Bioscience and its competitors with MarketBeat's FREE daily newsletter.

INVO Stock News Headlines

White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon bring Elon Musk's DOGE operation to its final, dramatic conclusion - with huge consequences for millions of investors. So if you have any money in the market... you're almost out of time to prepare. This plan has already been put in place... and can operate even if Elon's long gone from Washington.
NAYA Biosciences Inc trading halted, news pending
NAYA Biosciences to effect 1-for-12 reverse split
See More Headlines

INVO Stock Analysis - Frequently Asked Questions

INVO Bioscience's stock was trading at $0.81 at the start of the year. Since then, INVO shares have increased by 107.4% and is now trading at $1.68.
View the best growth stocks for 2025 here
.

INVO Bioscience, Inc. (NASDAQ:INVO) issued its quarterly earnings results on Monday, November, 15th. The company reported ($4.80) earnings per share for the quarter, missing analysts' consensus estimates of ($4.00) by $0.80. The business earned $0.22 million during the quarter, compared to analysts' expectations of $0.25 million.

Shares of INVO Bioscience reverse split before market open on Thursday, July 27th 2023. The 1-20 reverse split was announced on Thursday, July 27th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, July 27th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Shares of INVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that INVO Bioscience investors own include NVIDIA (NVDA), NIO (NIO), Tesla (TSLA), Meta Platforms (META), Nikola (NKLA), Broadcom (AVGO) and Bilibili (BILI).

Company Calendar

Last Earnings
11/15/2021
Today
5/25/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:INVO
Fax
N/A
Employees
25
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-8,030,000.00
Net Margins
-122.79%
Pretax Margin
-122.32%

Debt

Sales & Book Value

Annual Sales
$5.77 million
Price / Cash Flow
N/A
Book Value
($2.06) per share
Price / Book
-0.82

Miscellaneous

Free Float
3,769,000
Market Cap
$6.40 million
Optionable
No Data
Beta
1.43
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:INVO) was last updated on 5/25/2025 by MarketBeat.com Staff
From Our Partners